Key clinical point: An expert panel has provided new recommendations on the use of Oncotype DX in guiding treatment decisions for women with early-stage invasive breast cancer.
Major finding: In patients with Oncotype DX recurrence scores of less than 26, there is minimal to no benefit from chemotherapy, particularly for those greater than age 50 years.
Study details: A clinical practice guideline update released by the American Society of Clinical Oncology.
Disclosures: The study was funded by ASCO. The authors reported financial affiliations with AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Roche, and several others.
Andre F et al. J Clin Oncol. 2019 May 31. doi: 10.1200/JCO.19.00945.